DE60132611D1 - Substituierte benzimidazol-2-one als vasopressin receptor antagonisten und neuropeptide y modulatoren - Google Patents

Substituierte benzimidazol-2-one als vasopressin receptor antagonisten und neuropeptide y modulatoren

Info

Publication number: DE60132611D1
Authority: DE; Germany
Prior art keywords: neuropeptide; modulators; receptor antagonists; vasopressin receptor; ischemia
Prior art date: 2000-10-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE60132611T

Other languages

English (en)

Other versions

DE60132611T2 (de

Inventor

Maud J Urbanski

Joseph W Gunnet

Keith T Demarest

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Pharmaceuticals Inc

Original Assignee

Ortho McNeil Pharmaceutical Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-27

Filing date

2001-10-23

Publication date

2008-03-13

2001-10-23 Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc

2008-03-13 Application granted granted Critical

2008-03-13 Publication of DE60132611D1 publication Critical patent/DE60132611D1/de

2009-02-19 Publication of DE60132611T2 publication Critical patent/DE60132611T2/de

2021-10-24 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

101710151321 Melanostatin Proteins 0.000 title abstract 2
MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical class C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 title abstract 2
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 title abstract 2
239000002536 vasopressin receptor antagonist Substances 0.000 title abstract 2
102100028427 Pro-neuropeptide Y Human genes 0.000 title 1
206010019280 Heart failures Diseases 0.000 abstract 2
208000000044 Amnesia Diseases 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
206010003225 Arteriospasm coronary Diseases 0.000 abstract 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
208000003890 Coronary Vasospasm Diseases 0.000 abstract 1
208000005171 Dysmenorrhea Diseases 0.000 abstract 1
206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
206010016807 Fluid retention Diseases 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
208000026139 Memory disease Diseases 0.000 abstract 1
206010029164 Nephrotic syndrome Diseases 0.000 abstract 1
102400000064 Neuropeptide Y Human genes 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
206010030113 Oedema Diseases 0.000 abstract 1
208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 abstract 1
208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 abstract 1
208000001647 Renal Insufficiency Diseases 0.000 abstract 1
201000001880 Sexual dysfunction Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
208000007536 Thrombosis Diseases 0.000 abstract 1
206010047163 Vasospasm Diseases 0.000 abstract 1
208000027418 Wounds and injury Diseases 0.000 abstract 1
230000016571 aggressive behavior Effects 0.000 abstract 1
208000022531 anorexia Diseases 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
230000027288 circadian rhythm Effects 0.000 abstract 1
208000019425 cirrhosis of liver Diseases 0.000 abstract 1
201000011634 coronary artery vasospasm Diseases 0.000 abstract 1
230000006378 damage Effects 0.000 abstract 1
206010061428 decreased appetite Diseases 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
201000001421 hyperglycemia Diseases 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
208000028867 ischemia Diseases 0.000 abstract 1
201000006370 kidney failure Diseases 0.000 abstract 1
230000006984 memory degeneration Effects 0.000 abstract 1
208000023060 memory loss Diseases 0.000 abstract 1
208000031225 myocardial ischemia Diseases 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
231100000872 sexual dysfunction Toxicity 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Gynecology & Obstetrics (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DE60132611T 2000-10-27 2001-10-23 Substituierte benzimidazol-2-one als vasopressin receptor antagonisten und neuropeptide y modulatoren Expired - Fee Related DE60132611T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US24381700P	2000-10-27	2000-10-27
US243817P		2000-10-27
PCT/US2001/051108 WO2002055514A2 (en)	2000-10-27	2001-10-23	Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators

Publications (2)

Publication Number	Publication Date
DE60132611D1 true DE60132611D1 (de)	2008-03-13
DE60132611T2 DE60132611T2 (de)	2009-02-19

Family

ID=22920251

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60132611T Expired - Fee Related DE60132611T2 (de)	2000-10-27	2001-10-23	Substituierte benzimidazol-2-one als vasopressin receptor antagonisten und neuropeptide y modulatoren

Country Status (9)

Country	Link
EP (1)	EP1330451B1 (de)
JP (1)	JP2004517872A (de)
AT (1)	ATE384711T1 (de)
AU (1)	AU2002243419A1 (de)
DE (1)	DE60132611T2 (de)
DK (1)	DK1330451T3 (de)
ES (1)	ES2300376T3 (de)
PT (1)	PT1330451E (de)
WO (1)	WO2002055514A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE414078T1 (de) *	2005-07-21	2008-11-15	Hoffmann La Roche	Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten
CN101528712B (zh)	2006-08-26	2013-10-30	Abbvie德国有限责任两合公司	取代的苯并咪唑酮衍生物、包含它们的药物以及其用途
WO2013085954A1 (en)	2011-12-06	2013-06-13	Janssen Pharmaceutica Nv	Substituted piperidinyl-carboxamide derivatives useful as scd 1 inhibitors
US9102669B2 (en)	2011-12-06	2015-08-11	Janssen Pharmaceutica Nv	Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors
PE20160203A1 (es) *	2013-08-19	2016-04-20	Hoffmann La Roche	Antagonistas de via para tratar trastornos del sueno por cambio de fase
JP7426939B2 (ja) *	2018-03-01	2024-02-02	トーマス・ヘレデイズ・スティフテルス・フォー・メディシンスク・フォルスクニング	置換ベンゾジアゾールおよび療法におけるその使用
TW202313598A (zh) *	2021-05-26	2023-04-01	日商住友製藥股份有限公司	苯基尿素衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3318900A (en) *	1964-05-06	1967-05-09	Janssen Pharmaceutica Nv	Derivatives of benzimidazolinyl piperidine
ATE216580T1 (de) *	1993-07-16	2002-05-15	Merck & Co Inc	Benzoxazinon- und benzopyrimidinon- piperidinyl- verbindungen als tokolytische oxytocin-rezeptor- antagonisten
US6057338A (en) *	1997-04-04	2000-05-02	Merck & Co., Inc.	Somatostatin agonists
US6329389B1 (en) *	1998-04-08	2001-12-11	Takeda Chemical Industries, Ltd.	Amine compounds, their production and use
AU6211499A (en) *	1998-09-30	2000-04-17	Merck & Co., Inc.	Benzimidazolinyl piperidines as cgrp ligands
GB9823873D0 (en) *	1998-10-30	1998-12-30	Pharmacia & Upjohn Spa	2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents

2001
- 2001-10-23 DK DK01989314T patent/DK1330451T3/da active
- 2001-10-23 ES ES01989314T patent/ES2300376T3/es not_active Expired - Lifetime
- 2001-10-23 AU AU2002243419A patent/AU2002243419A1/en not_active Abandoned
- 2001-10-23 AT AT01989314T patent/ATE384711T1/de not_active IP Right Cessation
- 2001-10-23 WO PCT/US2001/051108 patent/WO2002055514A2/en not_active Ceased
- 2001-10-23 EP EP01989314A patent/EP1330451B1/de not_active Expired - Lifetime
- 2001-10-23 PT PT01989314T patent/PT1330451E/pt unknown
- 2001-10-23 JP JP2002556183A patent/JP2004517872A/ja active Pending
- 2001-10-23 DE DE60132611T patent/DE60132611T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2002055514A2 (en)	2002-07-18
EP1330451B1 (de)	2008-01-23
AU2002243419A1 (en)	2002-07-24
DE60132611T2 (de)	2009-02-19
ES2300376T3 (es)	2008-06-16
ATE384711T1 (de)	2008-02-15
EP1330451A2 (de)	2003-07-30
WO2002055514A3 (en)	2002-11-21
DK1330451T3 (da)	2008-11-10
PT1330451E (pt)	2008-03-13
JP2004517872A (ja)	2004-06-17

Publication	Publication Date	Title
MY135688A (en)	2008-06-30	Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators
SE0103644D0 (sv)	2001-11-01	Therapeutic isoquinoline compounds
SE0103649D0 (sv)	2001-11-01	Therapeutic quinoline compounds
CA2379640A1 (en)	2001-04-05	Certain alkylene diamine-substituted heterocycles
WO2002055012A3 (en)	2002-11-14	Therapeutic heterocyclic compounds
NO20032861L (no)	2003-08-21	Heteroarylurea nevropeptid Y Y5-reseptorantagonister
EA200300064A1 (ru)	2003-06-26	Карбоксамидные соединения и их применение в качестве антагонистов 11cby-рецептора человека
FI920217A0 (fi)	1992-01-17	Angiotensin ii receptor blockerande 2,3,6-substituerade kinazolinoner.
WO2003053922A3 (en)	2003-10-16	Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
NO20042141L (no)	2004-07-22	Terapeutiske quinolonforbindelser med 5-HT-antagonistiske egenskaper
EA200600315A1 (ru)	2006-06-30	Пиримидиновые соединения, их применение в качестве a-селективных антагонистов и способ их получения
CA2469813A1 (en)	2003-06-26	Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
ATE362473T1 (de)	2007-06-15	1,5-disubstituierte 3,4-dihydro-1h-4,5- döpyrimidin-2-on-verbindungen und ihre verwendung in der behandlung von durch csbp/p38 kinase beeinflussten krankheiten
ATE384711T1 (de)	2008-02-15	Substituierte benzimidazol-2-one als vasopressin receptor antagonisten und neuropeptide y modulatoren
ZA201102735B (en)	2012-12-27	Antagonists of the vanilloid receptor subtype 1(vr1) and uses thereof
CY1108703T1 (el)	2014-04-09	Αλλοστερικοι ρυθμιστες μεταβολοτροπων υποδοχεων γλουταμικου
PE20081876A1 (es)	2008-12-27	Aminoamidas como antagonistas de orexina
EA200600860A1 (ru)	2006-08-25	Производные n-тиазол-2-илбензамида
ATE305454T1 (de)	2005-10-15	Nichtpeptidische substituierte spirobenzoazepine als vasopressin antagonisten
PE20060770A1 (es)	2006-10-03	Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1
WO2001004139A3 (en)	2001-05-31	Human axor29 receptor
TW200515911A (en)	2005-05-16	Substituted spirobenzazepines
ATE330605T1 (de)	2006-07-15	Piperidin-2,6-dionpamoat-salze und ihre verwendung zur behanldung von stressbedingten affektiven st rungen
ATE415390T1 (de)	2008-12-15	Neue aminopyridinderivate als mglur5-antagonisten
SE0103650D0 (sv)	2001-11-01	Therapeutic heterocyclic compounds

Legal Events

Date	Code	Title	Description
2009-02-12	8364	No opposition during term of opposition
2010-08-19	8339	Ceased/non-payment of the annual fee